Stay updated on Safety of Single Dose UB-221 in Urticaria Clinical Trial
Sign up to get notified when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.

Latest updates to the Safety of Single Dose UB-221 in Urticaria Clinical Trial page
- Check2 days agoChange DetectedThe page footer site revision/version was updated from v3.5.2 to v3.5.3.SummaryDifference0.1%

- Check9 days agoChange DetectedThe revision label was updated from v3.5.0 to v3.5.2.SummaryDifference0.1%

- Check16 days agoNo Change Detected
- Check38 days agoChange DetectedRevision v3.5.0 was added and v3.4.3 removed, reflecting an update to the study protocol version.SummaryDifference0.1%

- Check45 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a maintenance/versioning update that does not modify the study details or other substantive content on the page.SummaryDifference0.1%

- Check74 days agoChange DetectedRevision: v3.4.2 was added and the funding-lapse notice (v3.4.1) was removed. There are no changes to the core study details, eligibility criteria, or outcomes.SummaryDifference0.5%

- Check81 days agoChange DetectedNotice about a lapse in government funding is added, informing users that the site may not be up to date and inquiries may be delayed, along with a status note about the NIH Clinical Center's operating status; the page revision changed from v3.4.0 to v3.4.1. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

Stay in the know with updates to Safety of Single Dose UB-221 in Urticaria Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Safety of Single Dose UB-221 in Urticaria Clinical Trial page.